eMedicine Specialties > Neurology > Inflammatory and Demyelinating Diseases

Temporal/Giant Cell Arteritis: Differential Diagnoses & Workup

Author: Tarakad S Ramachandran, MBBS, FRCP(C), FACP, Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital
Coauthor(s): Arun Ramachandran, State University of New York Upstate Medical University
Contributor Information and Disclosures

Updated: Jun 22, 2009

Differential Diagnoses

Cluster Headache
Persistent Idiopathic Facial Pain
Confusional States and Acute Memory Disorders
Polyarteritis Nodosa
Migraine Variants
Postherpetic Neuralgia
Multi-infarct Dementia
Trigeminal Neuralgia

Other Problems to Be Considered

Dental conditions
Infections
Sinus disease
Granulomatous angiitis of the CNS
Wegener granulomatosis
Horner syndrome
Carotid disease and stroke
Dissection
Connective tissue disease

Workup

Laboratory Studies

Temporal arteritis is a clinical diagnosis without a criterion standard serological or histological test. According to Ortiz, the lack of a gold standard bedevils the establishment of an accurate diagnosis.11

An elevated erythrocyte sedimentation rate (ESR) is generally well accepted in the diagnosis of giant cell arteritis. Because normal values of ESR are known to increase with age and are higher in women, the ESR should be adequately adjusted.12

ESR is elevated in most patients, often to a high level (mean, 85 ± 32 mm in 1 h), although it is normal in roughly 3% of patients. ESR often drops when steroid therapy is started, even in patients with normal baseline. Salvarani et al reported that before treatment, ESR may be normal in 7-20% of patients with giant cell arteritis.13 Therefore, a normal ESR does not rule out GCA, and the level of elevation of ESR does not correlate with the severity of the disease.

C-reactive protein (CRP), fibrinogen, complete blood count, and platelets should always be obtained in addition to the ESR.

  • The CRP is of hepatic origin, usually rises before ESR in most disease states, and is often elevated in giant cell arteritis. It has higher sensitivity and specificity than ESR (98.6% and 75.7%, respectively) and has relative insensitivity to age, gender, and other hematologic parameters.14
  • Since there can be nonconcordance between those 2 tests (either an elevated ESR with normal CRP or a normal ESR with an elevated CRP), the use of both tests provides a slightly greater sensitivity for the diagnosis of giant cell arteritis (GCA) (sensitivity of 99%) than the use of either test alone.15
  • CBC reveals mild anemia in most patients, with a mean hemoglobin of 11.7 ± 1.6 g/dL; most have a mild thrombocytosis (mean platelet count, 427 ± 116 x 10 x 109/L).
  • Thrombocytosis (platelets >375,000) is more helpful for ruling in temporal arteritis than an elevated ESR.16 Conversely, normal platelets are more accurate for ruling out temporal arteritis than a normal ESR.16
  • Alpha-2 globulin and other acute phase reactants are elevated mildly but nonspecifically in 72%.
  • Mild elevations in serum aspartate aminotransferase (AST) and alkaline phosphatase occur in 15%.

Imaging Studies

  • The diagnostic power of high-resolution MRI and color-coded Doppler study (CCDS) in detecting giant cell arteritis is comparable. Either of these noninvasive techniques may have value in the evaluation of patients with suspected GCA, and decisions regarding which technique to use may depend on the clinical setting.17 The ultrasonographic axial plan can show a concentric halo and T2-weigted MRI, a slightly hyperintense vessel wall due to inflammatory mural thickening of arteries.18  
  • On CT and MRI, the brain is typically unaffected by GCA, but in patients with a multi-infarct state due to cervicocephalic arteritis, CT and MRI demonstrate multiple areas of infarction.
    • Because aortic or other vessel aneurysms are often asymptomatic, unless they rupture, screening all patients with GCA for large vessel disease with CT scanning is prudent.
    • In GCA to evaluate aortic involvement. MRI may reveal vessel wall thickening and edema on T2-weighted images and increased mural enhancement on postcontrast T1-weighted images, indicative of regional inflammation. PET scanning with 18-fluorodeoxyglucose uptake has also been used to evaluate the vasculitic process within large vessels such as the thoracic aorta.19 The use of gallium-67 has been explored with a limited number of reports. The role of MRI and/or PET in establishing a diagnosis or tracking disease activity is under ongoing investigation.
  • Aortic arch and cerebral angiography
  • In pathologically proven cases, such as GACNS, the sensitivity of cerebral angiography findings is as low as 10–20%. Cerebral angiogram is not the procedure of choice in ascertaining the diagnosis of GACNS. However, involvement of multiple vessels in multiple vascular beds (high-probability angiogram) raises the possibility of RCVS (reversible cerebral vasoconstriction). Documentation of reversibility of the angiographic abnormalities, along the course of the disease, will eventually secure the diagnosis of RCVS.20
  • GCA causes granulomatous inflammation in the wall of medium-size and large arteries and preferentially affects extracranial branches of the carotid artery.21 Occlusion of the posterior ciliary arteries occur more commonly. Involvement of intracranial arteries is rare, and cerebral infarctions are the hemodynamic consequences of occlusion of cervical arteries. MR angiogram and cerebral angiogram reveal occlusion of the affected arteries. Vertebral arteries are more likely affected than internal carotid arteries, especially in the extradural portion, where there is more elastic tissue.22
    • Vertebral and external carotid arteries (including the superficial temporal artery) may show vasculitic changes of alternating stenotic segments or occlusion. Superficial temporal artery angiography is less reliable than TAB for establishing a diagnosis.
    • Internal carotid arteries may be occluded, but they rarely have a characteristic vasculitic pattern.
    • Subclavian, axillary, and proximal brachial arterial involvement produces a characteristic angiographic pattern of vasculitis that consists of long, smooth, stenotic segments alternating with nonstenotic segments and tapered occlusions.
  • While MR angiogram can give useful information in GCA, cerebral angiogram is the criterion standard to obtain optimum information, but at the cost of potential complications.

Other Tests

Superficial temporal artery biopsy (TAB) is the confirmatory test that should be obtained, almost without exception, in patients in whom GCA is suspected clinically.

Hematoxylin- and eosin-stained superficial tempor...

Hematoxylin- and eosin-stained superficial temporal artery biopsy specimen, cross section. The hallmark histologic features of GCA shown here include intimal thickening with luminal stenosis, mononuclear inflammatory cell infiltrate with media invasion and necrosis, and giant cell formation in the media.

Hematoxylin- and eosin-stained superficial tempor...

Hematoxylin- and eosin-stained superficial temporal artery biopsy specimen, cross section. The hallmark histologic features of GCA shown here include intimal thickening with luminal stenosis, mononuclear inflammatory cell infiltrate with media invasion and necrosis, and giant cell formation in the media.


  • TAB is the criterion standard for making a diagnosis of temporal arteritis and a positive biopsy is diagnostic (100% specificity). The histopathological changes often correlate with clinical features of severity, but the sensitivity of TAB is relatively low (15–40%). In most patients undergoing TAB, little evidence showed that clinical decision making with respect to corticosteroid therapy was influenced by the TAB result.23
  • TAB is important because of the long, often complicated, treatment course for GCA and since the other diagnostic possibilities that can mimic many of the nonspecific features of GCA (eg, headache, body aches, fatigue) are myriad.
  • In one large clinical series, TAB was confirmatory in only about one third of patients in whom GCA initially was suspected. Because of this high negative rate, and because GCA produces "skip lesions" with normal intervening segments, large (5 cm) and, if necessary, bilateral TAB specimens should be obtained.
  • Biopsy of the most symptomatic side should be performed first and, if frozen sections are negative, a contralateral specimen should also be obtained.
  • In cases in which a large TAB section is obtained from the most symptomatic side, and multiple thin sections obtained, diagnosis can be made in 86% of cases with a unilateral TAB.
  • TAB should be performed as soon as possible after clinical suspicion is raised, but it should not delay therapy when the index of suspicion is high because of the risk of ischemic ocular and cerebral complications.
  • The clinical significance of giant cells seen on TAB in temporal arteritis is unknown. Armstrong et al found that the presence of giant cells is not a significant factor in determining treatment or clinical progression of temporal arteritis. Their results showed the giant cell group to have 3 times the occurrence of blindness and polymyalgia rheumatica compared with the group with no giant cells, suggesting an association with giant cells and more aggressive disease.24
  • Alberts et al report that in clinical practice, bilateral temporal artery duplex served the same function as biopsy, but without subjecting patients to the potential morbidity of a surgical procedure. TAB could be reserved only for situations where the duplex result is inconsistent with the clinical picture, and the biopsy result, if different from the duplex result, might influence the treatment decision.25

Histologic Findings

The histopathology of the diagnostic arterial lesion includes intimal proliferation with resulting luminal stenosis, disruption of the internal elastic lamina by a mononuclear cell infiltrate, invasion and necrosis of the media progressing to panarteritic involvement by mononuclear cells, giant cell formation with granulomata within the mononuclear cell infiltrate and, less consistently, intravascular thrombosis.

Involvement of an affected artery is patchy with skip lesions and normal intervening segments. It is commonly accepted that because of the patchy involvement of the arteries, biopsies may be nondiagnostic in many patients, and nondiagnostic biopsy specimens do not exclude the diagnosis of temporal arteritis. Some authors even suggest that biopsy may not be necessary.26

Furthermore, corticosteroid therapy, which should be started without delay, rapidly reduces the chance of a positive biopsy result. One week of corticosteroid treatment may reduce the chance of obtaining a positive biopsy result to 10%, further suggesting that biopsy should be performed within the first few days of therapy.

Steroid therapy may change the vasculitic appearance within days, and a previous vasculitic focus may appear normal or show only intimal fibrosis.

More on Temporal/Giant Cell Arteritis

Overview: Temporal/Giant Cell Arteritis
Differential Diagnoses & Workup: Temporal/Giant Cell Arteritis
Treatment & Medication: Temporal/Giant Cell Arteritis
Follow-up: Temporal/Giant Cell Arteritis
Multimedia: Temporal/Giant Cell Arteritis
References

References

  1. Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A. Are polymyalgia rheumatica and giant cell arteritis the same disease?. Semin Arthritis Rheum. Apr 2004;33(5):294-301. [Medline].

  2. Eberhardt RT, Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev. Mar-Apr 2007;15(2):55-61. [Medline].

  3. Nordborg C, Larsson K, Aman P, Nordborg E. Expression of the class I interferon-related MxA protein in temporal arteries in polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol. Mar-Apr 2009;38(2):144-8. [Medline].

  4. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation. Jul 12 2005;112(2):264-9. [Medline].

  5. Mehler MF, Rabinowich L. The clinical neuro-ophthalmologic spectrum of temporal arteritis. Am J Med. Dec 1988;85(6):839-44. [Medline].

  6. Solans-Laqué R, Bosch-Gil JA, Molina-Catenario CA, Ortega-Aznar A, Alvarez-Sabin J, Vilardell-Tarres M. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis: report of 7 cases and review of the literature. Medicine (Baltimore). Nov 2008;87(6):335-44. [Medline].

  7. Onuma K, Chu CT, Dabbs DJ. Asymptomatic giant-cell (temporal) arteritis involving the bilateral adnexa: case report and literature review. Int J Gynecol Pathol. Jul 2007;26(3):352-5. [Medline].

  8. Adams WB, Becknell CA. Rare manifestation of scalp necrosis in temporal arteritis. Arch Dermatol. Aug 2007;143(8):1079-80. [Medline].

  9. Goicochea M, Correale J, Bonamico L, Dominguez R, Bagg E, Famulari A. Tongue necrosis in temporal arteritis. Headache. Sep 2007;47(8):1213-5. [Medline].

  10. Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry. Nov 2007;78(11):1255-9. [Medline].

  11. Ortiz Z, Tugwell P. Raised ESR in polymyalgia rheumatica no longer a sine qua non?. Lancet. Jul 6 1996;348(9019):4-5. [Medline].

  12. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. Mar 1997;123(3):285-96. [Medline].

  13. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. Jul 25 2002;347(4):261-71. [Medline].

  14. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. May-Jun 2004;14(3):245-57. [Medline].

  15. Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. Oct 2006;113(10):1842-5. [Medline].

  16. Foroozan R, Danesh-Meyer H, Savino PJ, Gamble G, Mekari-Sabbagh ON, Sergott RC. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology. Jul 2002;109(7):1267-71. [Medline].

  17. Bley TA, Reinhard M, Hauenstein C, Markl M, Warnatz K, Hetzel A. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum. Aug 2008;58(8):2574-8. [Medline].

  18. Reinhard M, Schmidt D, Schumacher M, Hetzel A. Involvement of the vertebral arteries in giant cell arteritis mimicking vertebral dissection. J Neurol. Aug 2003;250(8):1006-9. [Medline].

  19. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. Jan 2005;17(1):9-15. [Medline].

  20. Calabrese LH. Clinical management issues in vasculitis. Angiographically defined angiitis of the central nervous system: diagnostic and therapeutic dilemmas. Clin Exp Rheumatol. Nov-Dec 2003;21(6 Suppl 32):S127-30. [Medline].

  21. Warrington KJ, Matteson EL. Management guidelines and outcome measures in giant cell arteritis (GCA). Clin Exp Rheumatol. Nov-Dec 2007;25(6 Suppl 47):137-41. [Medline].

  22. Salvarani C, Giannini C, Miller DV, Hunder G. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum. Dec 15 2006;55(6):985-9. [Medline].

  23. Lenton J, Donnelly R, Nash JR. Does temporal artery biopsy influence the management of temporal arteritis?. QJM. Jan 2006;99(1):33-6. [Medline].

  24. Armstrong AT, Tyler WB, Wood GC, Harrington TM. Clinical importance of the presence of giant cells in temporal arteritis. J Clin Pathol. May 2008;61(5):669-71. [Medline].

  25. Alberts MS, Mosen DM. Diagnosing temporal arteritis: duplex vs. biopsy. QJM. Dec 2007;100(12):785-9. [Medline].

  26. Pountain G, Hazleman B. ABC of rheumatology. Polymyalgia rheumatica and giant cell arteritis. BMJ. Apr 22 1995;310(6986):1057-9. [Medline].

  27. Bley TA, Wieben O, Leupold J. Images in cardiovascular medicine. Magnetic resonance imaging findings in temporal arteritis. Circulation. Apr 26 2005;111(16):e260. [Medline].

  28. Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis. 1980;6:389-415.

  29. Caselli RJ. Giant cell (temporal) arteritis: a treatable cause of multi-infarct dementia. Neurology. May 1990;40(5):753-5. [Medline].

  30. Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology. May 1988;38(5):685-9. [Medline].

  31. Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am. Nov 1993;19(4):941-53. [Medline].

  32. Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. Mar 1988;38(3):352-9. [Medline].

  33. Fox GN. Giant cell arteritis. CMAJ. Dec 6 2005;173(12):1490; author reply 1490. [Medline].

  34. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore). Sep 2005;84(5):277-90. [Medline].

  35. Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum. Dec 15 2002;47(6):662-9. [Medline].

  36. Hollenhorst RW, Brown JR, Wagener HP, Shick RM. Neurologic aspects of temporal arteritis. Neurology. May 1960;10:490-8. [Medline].

  37. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. Feb 1978;88(2):162-7. [Medline].

  38. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med. Dec 1975;83(6):806-12. [Medline].

  39. Meyers AD, Said S. Temporal artery biopsy: concise guidelines for otolaryngologists. Laryngoscope. Nov 2004;114(11):2056-9. [Medline].

  40. Narváez J, Narváez JA, Nolla JM, Sirvent E, Reina D, Valverde J. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford). Apr 2005;44(4):479-83. [Medline].

  41. Ostberg G. Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand Suppl. 1972;533:135-59. [Medline].

  42. Polak P, Pokorny V, Stvrtina S, et al. Temporal arteritis presenting with paresis of the oculomotor nerve, and polymyalgia rheumatica, despite a low erythrocyte sedimentation rate. J Clin Rheumatol. Aug 2005;11(4):242-4. [Medline].

  43. Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol. Aug 31 2000;75 Suppl 1:S9-S15; discussion S17-9. [Medline].

  44. Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathologicalstudy to show the pattern of arterial involvement. Arch Neurol. Nov 1972;27(5):378-91. [Medline].

Further Reading

Keywords

cranial arteritis, giant cell arteritis, GCA, granulomatous arteritis, Horton syndrome, polymyalgia arteritica, polymyalgia rheumatica, polymyalgia, temporal arteritis, anterior ischemic optic neuropathy, AION

Contributor Information and Disclosures

Author

Tarakad S Ramachandran, MBBS, FRCP(C), FACP, Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital
Tarakad S Ramachandran, MBBS, FRCP(C), FACP is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners, American College of International Physicians, American College of Managed Care Medicine, American College of Physicians, American Heart Association, American Stroke Association, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, and Royal Society of Medicine
Disclosure: Abbott Labs  Honoraria Consulting; Teva Marion Honoraria Consulting; Boeringer-Ingelheim Honoraria Speaking and teaching

Coauthor(s)

Arun Ramachandran, State University of New York Upstate Medical University
Arun Ramachandran is a member of the following medical societies: American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Jorge E Mendizabal, MD, Consulting Staff, Corpus Christi Neurology
Jorge E Mendizabal, MD is a member of the following medical societies: American Academy of Neurology, American Headache Society, National Stroke Association, and Stroke Council of the American Heart Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Florian P Thomas, MD, MA, PhD, Drmed, Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University
Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Paraplegia Society, and National Multiple Sclerosis Society
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Michael K Racke, MD, Professor of Neurology and Molecular Virology, Immunology, and Medical Genetics, Chairman of Neurology, Chief of Neurology Service, Ohio State University Medical Center
Michael K Racke, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association for the Advancement of Science, American Association of Immunologists, and American Neurological Association
Disclosure: Teva Neuroscience Consulting fee Consulting; Peptimmune Inc. Consulting fee Consulting; Bristol Myers Squibb Consulting fee Consulting; EMD Serono Honoraria Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.